Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective State
Open accessAbstract
To the Editor: The study by Leon et al. (Dec.3 issue) 1 comparing three antithrombotic-drug regimens -aspirin alone, aspirin and warfarin, and aspirin and ticlopidineafter coronary stenting showed a lower rate of stent thrombosis with aspirin and ticlopidine, although there were more hemorrhagic complications than with aspirin alone.By contrast, there were no significant differences in the incidence of neutropenia or thrombocytopenia among the three regimens (overall incidence, 0.3 percent).Despite the absence of severe hematologic dyscrasias in the study, the authors refer to reports of the risk of serious hematologic complications, such as thrombotic thrombocytopenic purpura, among patients who received ticlopidine after coronary stent placement.However, they did not mention the risk of aplastic anemia, a life-threatening condition that may be induced by ticlopidine.Recently, Yeh et al. reviewed the cases of ticlopidine-induced aplastic anemia published in the English literature, 2 and four other cases have been reported 3,4 (including one case reported by us).Ten of 23 patients died (43 percent): 7 because of infection (candidal and gram-negative sepsis) and 1 from massive gastrointestinal bleeding.The only factor significantly correlated with survival was the patients' age.Other factors, such as sex, duration of ticlopidine use, and the presence of agranulocytosis at onset, had no prognostic value. 2 Although the pathogenesis of marrow toxicity related to this drug is still unclear, both direct toxicity and immunologic effects have been proposed. 2The therapeutic use of hematopoietic growth factors has been suggested, 4 but this treatment seems to have little effect on survival. 2,3n summary, although it is an infrequent event, ticlopi-dine-induced marrow aplasia is possible, and patients and doctors should be aware of it.However, aplastic anemia, like other hematologic dyscrasias induced by ticlopidine, appears after 2 weeks of treatment, 2-4 whereas stent thrombosis generally occurs within the first 14 days after coronary stenting (a mean of 0.7 day in the study by Leon et al.). 1 So, we agree with the suggestion made by Leon et al.to shorten the duration of ticlopidine therapy after stenting to two weeks.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Vulnerability to immunotherapy-induced depression involves both psychological and physiological risk factors, as indicated by higher pre-treatment depression scores and enhanced pituitary-adrenal response after first IFN-α injection in patients who developed psychological symptoms.
“The patients who developed psychological symptoms of depression scored higher on a depression scale before immunotherapy was started51 and had an enhanced pituitary–adrenal response following the first injection of IFN-α52, indicating that vulnerability to immunotherapy-induced depression involves both psychological and physiological risk factors.”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
Kirkwood, J. M., Strawderman, M. H., Ernstoff, M. S., Smith, T. J., Borden, E. C., & Blum, R. H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.1.7 · Cited by 2,089 · see citing works
Cole, B. F., Gelber, R. D., Kirkwood, J. M., Goldhirsch, A., Barylak, E., & Borden, E. C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2666 · Cited by 204 · see citing works
A perspective on the clinical effectiveness and tolerance of interferon-alpha.
Borden, E. C., & Parkinson, D. (1998) · PubMed · Cited by 99 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Opelz G, Sengar DP, Mickey MR, Terasaki PI. Effect of blood trans- fusions on subsequent kidney transplants. Transplant Proc 1973;5:253- 9.
- Opelz G. Improved kidney graft survival in nontransfused recipients. Transplant Proc 1987;19:149-52.
- Opelz G, Vanrenterghem Y, Kirste G, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplanta- tion 1997;63:964-7.
- responsibility; it requires careful consideration of several medical, scientific, and legal issues in which the school or university also has important and legitimate interests. The fundamental relationship between the amateur athlete and the school is consensual, and the law does not create a le- gal right to participate in any activity involving a potential risk of serious injury or sudden death. This view, affirmed by the appellate court in Knapp v. Northwestern University, explicitly supports the legal right of the school and the team physician (as well as the recommendations of the 26th Bethesda Conference 2 ) to disqualify competitive ath- letes with important cardiovascular abnormalities, ulti- mately for the purpose of protecting the health and wel- fare of young sports participants.
Cited by
Sorted by citations
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 396 · see citing works
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395 · see citing works
Outcomes in Young Adulthood for Very-Low-Birth-Weight Infants
Hack, M., Flannery, D. J., SCHLUCHTER, M. D., Cartar, L., Borawski, E. A., & Klein, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010856 · Cited by 1,200 · see citing works
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120 · see citing works
Cytokine-induced sickness behaviour: mechanisms and implications
Konsman, J. P., Parnet, P., & Dantzer, R. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02088-9 · Cited by 999 · see citing works
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862 · see citing works
Cytokine‐Induced Sickness Behavior: Mechanisms and Implications
Dantzer, R. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05827.x · Cited by 808 · see citing works
Cytokine, Sickness Behavior, and Depression
Dantzer, R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.002 · Cited by 789 · see citing works
Harrison, N. A., Brydon, L., Walker, C., Gray, M. A., Steptoe, A., & Critchley, H. D. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.015 · Cited by 756 · see citing works
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726 · see citing works
The olfactory bulbectomised rat as a model of depression
Song, C., & Leonard, B. E. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.03.010 · Cited by 700 · see citing works
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483 · see citing works
Self-citationCapuron, L., Ravaud, A., Neveu, P. J., Miller, A. H., Maes, M., & Dantzer, R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4000995 · Cited by 473 · see citing works
Self-citationNeuropsychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review
Dieperink, E. W., Willenbring, M., & Ho, S. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.867 · Cited by 417 · see citing works
Psychosocial factors in dialysis patients
Kimmel, P. L. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0590041599.x · Cited by 391 · see citing works
Serotonergic vulnerability and depression: assumptions, experimental evidence and implications
Jans, L. A. W., Riedel, W. J., Markus, C. R., & Blokland, A. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001920 · Cited by 372 · see citing works
Cytokine, sickness behavior, and depression
Dantzer, R. (2006) · Neurologic Clinics · doi:10.1016/j.ncl.2006.03.003 · Cited by 340 · see citing works
Anisman, H., Merali, Z., & Hayley, S. P. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 334 · see citing works
A Starring Role for Microglia in Brain Sex Differences
Lenz, K. M., & McCarthy, M. M. (2015) · The Neuroscientist · doi:10.1177/1073858414536468 · Cited by 281 · see citing works
Inflammatory markers in late-life depression: Results from a population-based study
Bremmer, M. A., Beekman, A. T. F., Deeg, D. J. H., Penninx, B. W. J. H., Dik, M. G., Hack, C. E., & Hoogendijk, W. J. G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.07.002 · Cited by 326 · see citing works
Schaefer, M., Schmidt, F., Folwaczny, C., Lorenz, R. L., Martin, G., Schindlbeck, N. E., Heldwein, W., Soyka, M., Grunze, H., Koenig, A., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50031 · Cited by 321 · see citing works
Hauser, P., Khosla, J., Aurora, H., Laurin, J. M., Kling, M. A., Hill, J., Gulati, M. S., Thornton, A. J., Schultz, R. L., Valentine, A. D., et al. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001119 · Cited by 309 · see citing works
A Dialogue between the Immune System and Brain, Spoken in the Language of Serotonin
Baganz, N. L., & Blakely, R. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300186b · Cited by 308 · see citing works
Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy
Raison, C. L., Borisov, A. S., Broadwell, S. D., Capuron, L., Woolwine, B. J., Jacobson, I. M., Nemeroff, C. B., & Miller, A. H. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0106 · Cited by 298 · see citing works
Self-citationCapuron, L., Ravaud, A., & Dantzer, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2143 · Cited by 293 · see citing works
Self-citationCytokines and depression: The need for a new paradigm
Capuron, L., & Dantzer, R. (2003) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00078-8 · Cited by 280 · see citing works
Self-citationMiller, A. H. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.08.006 · Cited by 261 · see citing works
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240 · see citing works
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2003) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 237 · see citing works
Self-citationMendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229 · see citing works
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228 · see citing works
The phenomenology and treatment of interferon-induced depression
Loftis, J. M., & Hauser, P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.04.002 · Cited by 227 · see citing works
Hepatitis C, interferon alfa, and depression
Zdilar, D., Franco-Bronson, K., Buchler, N. M., Locala, J. A., & Younossi, Z. M. (2000) · Hepatology · doi:10.1053/jhep.2000.7880 · Cited by 213 · see citing works
Capuron, L., Ravaud, A., Gualde, N., Bosmans, E., Dantzer, R., Maes, M., & Neveu, P. J. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00030-0 · Cited by 201 · see citing works
Interferon alpha (IFNα) and psychiatric syndromes
Schaefer, M., Engelbrechta, M. A., Gut, O., Fiebich, B. L., Bauer, J., Schmidt, F., Grunze, H., & Lieb, K. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00324-4 · Cited by 203 · see citing works
Baune, B. T., Dannlowski, U., Domschke, K., Janssen, D. G. A., Jordan, M. A., Ohrmann, P., Bauer, J., Biroš, E., Arolt, V., Kugel, H., et al. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.004 · Cited by 193 · see citing works
Cytokines and depression: fortuitous or causative association?
Dantzer, R., Wollman, E., Vitkovic, L., & Yirmiya, R. (1999) · Molecular Psychiatry · doi:10.1038/sj.mp.4000572 · Cited by 174 · see citing works
Asnis, G. M., & Garza, R. D. L. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000210099.36500.fe · Cited by 170 · see citing works
Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery
Remus, J. L., & Dantzer, R. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw028 · Cited by 166 · see citing works
Effects of antidepressants on cytokine production and actions
Castanon, N., Leonard, B. E., Neveu, P. J., & Yirmiya, R. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00008-9 · Cited by 143 · see citing works
Alcoholism and inflammation: Neuroimmunology of behavioral and mood disorders
Kelley, K. W., & Dantzer, R. (2010) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2010.12.013 · Cited by 143 · see citing works
Horikawa, N., Yamazaki, T., Izumi, N., & Uchihara, M. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(02)00239-6 · Cited by 140 · see citing works
Treatment of cytokine-induced depression
Capuron, L., Hauser, P., Hinze-Selch, D., Miller, A. H., & Neveu, P. J. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00007-7 · Cited by 132 · see citing works
Self-citationSomatization: A psychoneuroimmune perspective
Dantzer, R. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.03.011 · Cited by 130 · see citing works
Reichenberg, A., Gorman, J. M., & Dieterich, D. T. (2005) · AIDS · doi:10.1097/01.aids.0000192087.64432.ae · Cited by 129 · see citing works
Laumet, G. O., Edralin, J. D., Chiang, A. C. A., Dantzer, R., Heijnen, C. J., & Kavelaars, A. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0154-1 · Cited by 107 · see citing works
Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?
Schaefer, M., Heinz, A., & Backmund, M. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00821.x · Cited by 107 · see citing works
Lasselin, J., Lekander, M., Axelsson, J., & Karshikoff, B. (2018) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.06.005 · Cited by 106 · see citing works
Thombs, B. D., van Lankveld, W., Bassel, M., Baron, M. G., Buzza, R., Haslam, S., Haythornthwaite, J. A., Hudson, M., Jewett, L. R., Knafo, R., et al. (2010) · Arthritis Care & Research · doi:10.1002/acr.20187 · Cited by 102 · see citing works
Depression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100 · see citing works
Cognitive Dysfunction and Depression During Treatment With Interferon-Alpha and Chemotherapy
Scheibel, R. S., Valentine, A. D., O'Brien, S. M., & Meyers, C. A. (2004) · Journal of Neuropsychiatry · doi:10.1176/jnp.16.2.185 · Cited by 98 · see citing works
A Biological Substrate for Somatoform Disorders: Importance of Pathophysiology
Dimsdale, J. E., & Dantzer, R. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31815b00e7 · Cited by 94 · see citing works
Hepatitis C, alpha interferon, anxiety and depression disorders: A prospective study of 71 patients
Gohier, B., Goëb, J.-L., Rannou-Dubas, K., Fouchard, I., Calès, P., & Garré, J.-B. (2003) · The World Journal of Biological Psychiatry · doi:10.1080/15622970310029904 · Cited by 87 · see citing works
Psychiatric and Substance Use Disorders in Individuals with Hepatitis C: Epidemiology and Management
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006) · Drugs · doi:10.2165/00003495-200666020-00003 · Cited by 86 · see citing works
Martín‐Santos, R., Díez, C., Castellví, P., Navinés, R., Miquel, M., Masnou, H., Soler, A., Ardévol, M., GARCÍA, F., Galeras, J. A., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03568.x · Cited by 79 · see citing works
HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations
Backus, L. I., Boothroyd, D. B., & Deyton, L. (2005) · AIDS · doi:10.1097/01.aids.0000192065.09281.01 · Cited by 77 · see citing works
Gene expression biomarkers of response to citalopram treatment in major depressive disorder
Mamdani, F., Berlim, M. T., Beaulieu, M.-M., Labbe, A., Mérette, C., & Turecki, G. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.12 · Cited by 72 · see citing works
Poon, D. C.-H., Ho, J. Y. S., Chiu, K., Wong, H.-L., & Chang, R. C. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.015 · Cited by 68 · see citing works
Neuropsychiatric Toxicity of Antiviral Treatment in Chronic Hepatitis C
Fontana, R. J. (2000) · Digestive Diseases · doi:10.1159/000051384 · Cited by 67 · see citing works
Neurobehavioral effects of interferon therapy
Valentine, A. D., & Meyers, C. A. (2005) · Current Psychiatry Reports · doi:10.1007/s11920-005-0042-3 · Cited by 67 · see citing works
Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C
Evon, D. M., Ramcharran, D., Belle, S. H., Terrault, N. A., Fontana, R. J., & Fried, M. W. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.528 · Cited by 63 · see citing works
Franzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.02.011 · Cited by 62 · see citing works
Back to the future of psychoneuroimmunology: Studying inflammation-induced sickness behavior
Lasselin, J. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100379 · Cited by 65 · see citing works
Antidepressant reversal of interferon-α-induced anhedonia
Sammut, S., Bethus, I., Goodall, G., & Muscat, R. (2002) · Physiology & Behavior · doi:10.1016/s0031-9384(02)00677-7 · Cited by 62 · see citing works
Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C
Amodio, P., De Toni, E. N., Cavalletto, L., Mapelli, D., Bernardinello, E., Del Piccolo, F., Bergamelli, C., Costanzo, R., Bergamaschi, F., Poma, S. Z., et al. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.09.004 · Cited by 61 · see citing works
Garza, R. D. L., & Asnis, G. M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02757-4 · Cited by 63 · see citing works
Managing Depression during Hepatitis C Treatment
Sockalingam, S., & Abbey, S. E. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400906 · Cited by 60 · see citing works
Interferon Alfa–Induced Adverse Effects in Patients with a Psychiatric Diagnosis
Pariante, C. M., Landau, S., & Carpiniello, B. (2002) · New England Journal of Medicine · doi:10.1056/nejm200207113470221 · Cited by 59 · see citing works
High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity
Fitzgibbon, M., Finn, D. P., & Roche, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv095 · Cited by 57 · see citing works
Interferon-induced depression: Strategies in treatment
Asnis, G. M., & Garza, R. D. L. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.006 · Cited by 57 · see citing works
Cognitive and neuropsychiatric disease manifestations in MS.
Feinstein, A., DeLuca, J., Baune, B., Filippi, M., & Lassman, H. (2013) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2012.08.001 · Cited by 68 · see citing works
Symptomatic Treatment of Interferon-α–Induced Depression in Hepatitis C
Baraldi, S., Hepgul, N., Mondelli, V., & Pariante, C. M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31825d9982 · Cited by 54 · see citing works
Neuropsychiatric side effects of interferon-alfa therapy.
Gool, A. R. V., Kruit, W. H. J., Stoter, G., Engels, F. K., & Eggermont, A. M. M. (2003) · Pharmacy World & Science · doi:10.1023/a:1022449613907 · Cited by 54 · see citing works
Schäfer, A., Wïttchen, H., Seufert, J., & Kraus, M. R. (2007) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.229 · Cited by 53 · see citing works
Patterson, A. L., Morasco, B. J., Fuller, B. E., Indest, D. W., Loftis, J. M., & Hauser, P. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.04.005 · Cited by 51 · see citing works
Acute interferon-α administration modulates sucrose consumption in the rat
Sammut, S., Goodall, G., & Muscat, R. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(00)00051-2 · Cited by 51 · see citing works
Loftis, J. M., Patterson, A. L., Wilhelm, C., McNett, H., Morasco, B. J., Huckans, M. S., Morgan, T. R. M., Saperstein, S., Asghar, A., & Hauser, P. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.10.012 · Cited by 50 · see citing works
Maes, M. H. J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00168-8 · Cited by 50 · see citing works
Mechanisms of antidepressant action: An integrated dopaminergic perspective
Porcelli, S., Drago, A., Fabbri, C., & Serretti, A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.03.005 · Cited by 49 · see citing works
Simmons, D. A., & Broderick, P. A. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.009 · Cited by 49 · see citing works
Schaefer, M., & Mauss, S. (2008) · Current Drug Abuse Reviews · doi:10.2174/1874473710801020177 · Cited by 46 · see citing works
Baune, B. T. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_19 · Cited by 46 · see citing works
Incidence of interferon alfa-induced depression in patients with chronic hepatitis C
Castéra, L., Zigante, F., Bastie, A., Buffet, C., Dhumeaux, D., & Hardy, P. (2002) · Hepatology · doi:10.1053/jhep.2002.32104 · Cited by 46 · see citing works
Sarkar, S., & Schaefer, M. (2013) · Psychosomatics · doi:10.1016/j.psym.2013.06.015 · Cited by 45 · see citing works
Fontana, R. J., Kronfol, Z., Lindsay, K. L., Bieliauskas, L. A., Padmanabhan, L., Back‐Madruga, C., Lok, A. S.-F., Stoddard, A. M., & the HALT-C Trial Group (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02106.x · Cited by 43 · see citing works
Interferon-induced depression: prevalence and management
Scalori, A., Pozzi, M., Bellia, V., Apale, P., Santamaria, G., Bordoni, T., Redaelli, A. E., Avolio, A. W., Parravicini, P., Pioltelli, P. E., et al. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.09.018 · Cited by 41 · see citing works
Psychological and behavioural effects of interferons
Bonaccorso, S., Meltzer, H. Y., & Maes, M. H. J. (2000) · Current Opinion in Psychiatry · doi:10.1097/00001504-200011000-00034 · Cited by 38 · see citing works
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40 · see citing works
Hepatitis C Treatment for People With Severe Mental Illness
Mistler, L. A., Brunette, M. F., Marsh, B. J., Vidaver, R. M., Luckoor, R., & Rosenberg, S. D. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.2.93 · Cited by 39 · see citing works
Heinze, S., Egberts, F., Rötzer, S., Volkenandt, M., Tilgen, W., Linse, R., Boettjer, J., VOGT, T. M., Spieth, K., Eigentler, T., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b8bdb9 · Cited by 39 · see citing works
Trained innate immunity: a salient factor in the pathogenesis of neuroimmune psychiatric disorders
Salam, A. P., Borsini, A., & Zunszain, P. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.186 · Cited by 39 · see citing works
Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C
Dbouk, N., Arguedas, M. R., & Sheikh, A. M. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9985-z · Cited by 38 · see citing works
Suicidal Ideation With IFN-α and Ribavirin in a Patient With Hepatitis C
Ademmer, K., Beutel, M. E., Bretzel, R. G., Clemens, J., & Reimer, C. (2001) · Psychosomatics · doi:10.1176/appi.psy.42.4.365 · Cited by 37 · see citing works
Risk factors for the development of depression in patients with hepatitis C taking interferon-α
Smith, K. J. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13917 · Cited by 35 · see citing works
Schäfer, A., Scheurlen, M., Seufert, J., Keicher, C., Weißbrich, B., Rieger, P., & Kraus, M. R. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.10.007 · Cited by 33 · see citing works
Cytokines, Sickness Behavior, and Depression
Dantzer, R., Bluthé, R.-M., Castanon, N., Kelley, K. W., Konsman, J. P., Layé, S., Lestage, J., & Parnet, P. (2007) · Elsevier eBooks · doi:10.1016/b978-012088576-3/50019-8 · Cited by 32 · see citing works
Quarantini, L. C., Bressan, R. A., Galvão, A., Batista-Neves, S. C., Paraná, R., & Miranda‐Scippa, Â. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01532.x · Cited by 29 · see citing works
Nitric oxide involvement in depression during interferon-alpha therapy
Suzuki, E., Yoshida, Y., Shibuya, A., & Miyaoka, H. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003766 · Cited by 29 · see citing works
Cytokines and depression: An update
Dantzer, R., Wollman, E. E., & Yirmiya, R. (2002) · Brain Behavior and Immunity · doi:10.1016/s0889-1591(02)00002-8 · Cited by 26 · see citing works
Cytokines in Clinical Psychiatry
Capuron, L., Bluthé, R.-M., & Dantzer, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1163 · Cited by 25 · see citing works
Self-citation
- Authors
- Capuron, L., & Ravaud, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1999-04-29
- Volume
- 340
- Issue
- 17
- Pages
- 1370-1370
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1986891518
- Cited by
- 169
- References
- 4
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 2 · 2018: 2 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 4 · 2012: 10
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Keywords
- interferon-alpha therapy, depression, affective states, treatment response prediction, interferon-induced depression
- MeSH terms
- Adult, Affect, Antineoplastic Agents, Depression, Female, Humans, Male, Melanoma, Psychiatric Status Rating Scales, Interferon-alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review